Myriad Genetics (MYGN) Q1 2025: $35M Guidance Cut Spotlights GeneSight and Hereditary Cancer Drag
Myriad Genetics’ Q1 2025 results underscored persistent execution headwinds as management cut full-year revenue guidance by $35 million, driven by weak GeneSight and hereditary cancer test volumes. While prenatal and oncology MyRisk tests posted double-digit growth, operational complexity and payer coverage changes weighed on results. Investors face a multi-quarter wait for portfolio clarity as the new CEO initiates a strategic review and prioritizes oncology as the company’s cornerstone.
Summary
- GeneSight and Unaffected Hereditary Cancer Underperformance: Volume and reimbursement headwinds forced a $35M revenue guidance reduction.
- Oncology and Prenatal Bright Spots: MyRisk and prenatal test volumes grew double digits, partially offsetting segment softness.
- Strategic Simplification Pending: Leadership signals a multi-quarter review to refocus the portfolio around core oncology strengths.
Performance Analysis
Myriad Genetics delivered Q1 revenue at the low end of its target range, down 3% year-over-year, with test volume up 1% but average revenue per test down 4%. The decline was primarily attributed to reimbursement headwinds for GeneSight, a pharmacogenomics test, following UnitedHealthcare’s coverage policy change, and flat volumes in unaffected hereditary cancer testing. Excluding one-time items and divestitures, management argued that underlying revenue would have grown 5% year-over-year, but this normalization masks the core volume and execution challenges in key product lines.
Prenatal (Foresight and Prequel) and oncology MyRisk tests were the quarter’s standouts, with volume growth of 10% and 11% year-over-year, respectively. However, this was offset by a 20% revenue decline in GeneSight and persistent flatness in unaffected hereditary cancer volumes, reflecting the slow ramp of EMR (electronic medical record) integrations and delayed impact from breast cancer risk assessment programs. Gross margins expanded by 50 basis points to 69% on lab efficiency gains, but adjusted EBITDA hovered near break-even and cash burn persisted. The company ended Q1 with $92M in cash and $42M in revolver availability, which management asserts is sufficient for 2025 operations.
- GeneSight Drag: UnitedHealthcare’s policy shift drove a $10M Q1 revenue headwind, with additional volume softness from resource reallocation.
- Hereditary Cancer Stagnation: Unaffected test volumes were flat, with workflow and EMR integration delays cited as the core bottleneck.
- Prenatal and Oncology Resilience: Double-digit test volume growth in Foresight, Prequel, and MyRisk partially offsetting segment underperformance.
The net impact is a $35M annual revenue guidance cut, with OpEx trimmed by $25M to preserve strategic growth investments. The new guide assumes only modest sequential revenue increases and reflects a more conservative outlook for both GeneSight and hereditary cancer testing in 2025.
Executive Commentary
"While we have had a disappointing start to the year, I'm as excited now as I was when I joined Myriad in December of 2023 about the potential for Myriad, the potential for sustained profitable growth, gaining market share, and positively impacting an increasing number of patient lives. The management team and I are now focused on unlocking that potential by ensuring we are pursuing a compelling strategy, strengthening our team and organizational capabilities, and improving execution."
Sam Raha, President and Chief Executive Officer
"Even with the Q1 revenue decline, we were able to expand our gross margins by 50 basis points, delivering a 69% gross margin. This year-over-year improvement reflects lab efficiencies and is a testament to the power of our scalable business model. We believe that our liquidity will be sufficient to meet our projected operating requirements through 2025, but we plan to continue to evaluate opportunities to further strengthen the balance sheet to ensure a multi-year liquidity runway."
Scott Loeffler, Chief Financial Officer
Strategic Positioning
1. Oncology as the Strategic Core
Leadership reaffirmed oncology as Myriad’s cornerstone, prioritizing the cancer care continuum from screening through therapy selection and monitoring. The MyRisk test, particularly for affected cancer patients, is positioned as the flagship, with 11% volume growth and ongoing investment in expanded panels and MRD (minimal residual disease) products targeting launch in 2026. The company’s partnership with Pathomic for AI-enabled biomarker testing further signals intent to differentiate in prostate and other cancers.
2. Portfolio Rationalization and Strategic Review
The new CEO initiated a portfolio review to simplify and focus the business, targeting clarity by late Q3 or Q4. Management indicated willingness to reevaluate “sacred cows” outside oncology, suggesting potential for divestitures or deprioritization of underperforming assets. The review will inform future capital allocation, with oncology and select women’s health initiatives likely to receive the bulk of investment.
3. Operational Execution and EMR Integration
EMR integration delays have materially hampered unaffected hereditary cancer test volume growth. Management detailed the complexity of integrating family history and patient education workflows into EMR systems, particularly for virtual appointments and unaffected populations. While solutions are being developed with partners like Epic, the fix is account-by-account and expected to take several quarters, limiting near-term growth.
4. GeneSight: Reimbursement and Commercial Model Reset
GeneSight’s revenue decline is structural, with UnitedHealthcare’s coverage loss driving a $10M Q1 hit and management pulling back commercial resources to focus on profitable growth. While provider ordering behavior remains stable, the company is optimizing patient payment options and revenue cycle management (RCM) to reduce high zero-pay rates and improve reimbursement.
5. Product Pipeline and Launch Discipline
Upcoming launches of First Gene (combined carrier screening and NIPS), AI-enabled Prolaris, and MRD tests are core to the growth narrative. Management emphasized the need for improved execution discipline, with a commitment to predictable, on-time launches and a more mature product development process.
Key Considerations
This quarter’s results highlight the need for sharper portfolio focus, operational discipline, and commercial execution as Myriad navigates reimbursement volatility and workflow bottlenecks.
Key Considerations:
- GeneSight’s Future Role: With payer headwinds and resource reallocation, GeneSight’s revenue contribution may remain structurally lower unless reimbursement expands.
- Oncology’s Growth Potential: MyRisk and future MRD products anchor management’s long-term growth thesis, but require near-term execution to regain investor confidence.
- EMR Integration as a Growth Bottleneck: Workflow complexity in unaffected hereditary cancer is a material drag, with a multi-quarter fix needed to unlock volume upside.
- Strategic Review Timeline: Investors should expect portfolio clarity and capital allocation priorities only by late Q3 or Q4, as the CEO’s review progresses.
- Liquidity and Cost Management: Sufficient cash for 2025 operations, but ongoing cash burn and a near break-even EBITDA highlight the need for continued cost discipline.
Risks
Myriad faces execution risk in EMR integration, reimbursement risk for key tests, and potential further payer coverage erosion beyond UnitedHealthcare. Delays in product launches or inability to scale new offerings could extend the current revenue stagnation. The slow pace of strategic review may prolong investor uncertainty, while ongoing cash burn and near break-even profitability limit margin for error if revenue growth does not materialize.
Forward Outlook
For Q2 and the remainder of 2025, Myriad guided to:
- Annual revenue of $807M to $823M, reflecting a $35M reduction from prior midpoint
- Gross margin range of 68.5% to 69.5%
- Adjusted OpEx of $555M to $565M, trimmed by $25M
- Adjusted EPS between a loss of $0.02 and a gain of $0.02
- Adjusted EBITDA of $19M to $27M
Management expects modest sequential revenue increases, with volume recovery in unaffected hereditary cancer and GeneSight remaining muted. Key launch milestones for First Gene and AI-enabled Prolaris are on track for late 2025, with MRD launch targeted for H1 2026.
- GeneSight and hereditary cancer volumes are expected to remain soft in the near term
- Strategic review outcomes and pipeline launches will drive the medium-term narrative
Takeaways
Myriad’s Q1 2025 results reinforce the need for strategic simplification and operational discipline.
- Guidance Reset: The $35M revenue cut reflects persistent volume and reimbursement headwinds, particularly in GeneSight and hereditary cancer.
- Oncology Focus: Management’s explicit prioritization of oncology, with double-digit growth in MyRisk, sets the stage for future portfolio rationalization.
- Execution Watch: Investors should monitor EMR integration progress, pipeline launch timelines, and the pace of strategic clarity as leading indicators of turnaround potential.
Conclusion
Myriad Genetics enters the remainder of 2025 in a holding pattern, with growth in core oncology and prenatal offset by GeneSight and hereditary cancer headwinds. The CEO’s multi-quarter strategic review and focus on execution will be critical in determining whether the company can reignite sustainable, profitable growth or remain mired in operational complexity.
Industry Read-Through
Myriad’s experience this quarter highlights persistent reimbursement volatility and workflow complexity as defining forces in molecular diagnostics. The UnitedHealthcare GeneSight coverage loss and EMR integration drag are cautionary signals for peers relying on payer coverage stability or rapid digital workflow adoption. For diagnostics companies, the ability to execute on EMR integration, diversify payer risk, and deliver on new product launches will increasingly separate winners from laggards. The focus on oncology as a resilient anchor mirrors broader industry trends, while the challenges in pharmacogenomics and hereditary cancer testing underscore the need for commercial and operational agility.